MaxCyte (NASDAQ:MXCT) Receives Overweight Rating from Stephens

MaxCyte (NASDAQ:MXCT)‘s stock had its “overweight” rating reaffirmed by investment analysts at Stephens in a report released on Tuesday, Benzinga reports. They currently have a $11.00 price objective on the stock. Stephens’ price target indicates a potential upside of 170.94% from the stock’s previous close.

MXCT has been the subject of several other research reports. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research report on Wednesday, March 13th. BTIG Research reduced their price objective on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th.

MaxCyte Price Performance

NASDAQ MXCT traded up $0.10 on Tuesday, hitting $4.06. 191,316 shares of the stock were exchanged, compared to its average volume of 631,630. MaxCyte has a 52 week low of $2.45 and a 52 week high of $5.55. The company has a market capitalization of $423.85 million, a PE ratio of -10.97 and a beta of 1.34. The business’s fifty day moving average is $4.29 and its 200 day moving average is $4.32.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. The firm had revenue of $15.67 million for the quarter, compared to the consensus estimate of $15.60 million. Analysts predict that MaxCyte will post -0.53 EPS for the current fiscal year.

Insider Buying and Selling at MaxCyte

In other news, Director John Joseph Johnston sold 5,000 shares of MaxCyte stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the sale, the director now owns 120,583 shares in the company, valued at $617,384.96. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On MaxCyte

Several large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. bought a new position in MaxCyte during the fourth quarter valued at $29,000. Victory Capital Management Inc. purchased a new stake in MaxCyte in the third quarter worth about $31,000. Johnson Investment Counsel Inc. purchased a new stake in MaxCyte in the third quarter worth about $34,000. Aigen Investment Management LP purchased a new stake in MaxCyte in the third quarter worth about $44,000. Finally, Nisa Investment Advisors LLC lifted its stake in MaxCyte by 47,100.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock worth $55,000 after acquiring an additional 11,775 shares during the period. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.